Cargando…

Reduced hypoglycaemia using liver‐targeted insulin in individuals with type 1 diabetes

AIM: To investigate whether an increased bolus: basal insulin ratio (BBR) with liver‐targeted bolus insulin (BoI) would increase BoI use and decrease hypoglycaemic events (HEv). PATIENT POPULATION AND METHODS: We enrolled 52 persons (HbA1c 6.9% ± 0.12%, mean ± SEM) with type 1 diabetes using multipl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weinstock, Ruth S., Bode, Bruce W., Garg, Satish K., Klonoff, David C., El Sanadi, Caroline, Geho, W. Blair, Muchmore, Douglas B., Penn, Marc S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546184/ https://www.ncbi.nlm.nih.gov/pubmed/35546449 http://dx.doi.org/10.1111/dom.14761

Ejemplares similares

Insulin Hypoglycæmia
Publicado: (1948)

Approach to assessing the economic impact of insulin‐related hypoglycaemia using the novel Local Impact of Hypoglycaemia Tool
por: Parekh, W. A., et al.
Publicado: (2015)

Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
por: Philis-Tsimikas, Athena, et al.
Publicado: (2020)

Making surgical wards safer for patients with diabetes: reducing hypoglycaemia and insulin errors
por: Singh, Aminder, et al.
Publicado: (2018)

Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia
por: Reviriego, J, et al.
Publicado: (2008)

Hypoglycaemia is reduced with use of inhaled Technosphere(®) Insulin relative to insulin aspart in type 1 diabetes mellitus
por: Seaquist, E. R., et al.
Publicado: (2019)

A meta‐analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia
por: Heller, S., et al.
Publicado: (2015)

Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin‐treated adults with type 2 diabetes and risk factors for hypoglycaemia
por: Goldenberg, Ronald M., et al.
Publicado: (2021)

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used
por: Norwood, Paul, et al.
Publicado: (2017)

Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials
por: Rosenstock, Julio, et al.
Publicado: (2016)

Hypoglycæmia
Publicado: (1934)

Accelerated Insulin Pharmacokinetics and Improved Postprandial Glycemic Control in Patients With Type 1 Diabetes After Coadministration of Prandial Insulins With Hyaluronidase
por: Hompesch, Marcus, et al.
Publicado: (2011)

Counter-regulatory responses to postprandial hypoglycaemia in patients with post-bariatric hypoglycaemia vs surgical and non-surgical control individuals
por: Tripyla, Afroditi, et al.
Publicado: (2023)

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials
por: Ratner, R E, et al.
Publicado: (2013)

Are we missing hypoglycaemia? Elderly patients with insulin-treated diabetes present to primary care frequently with non-specific symptoms associated with hypoglycaemia
por: Hope, Suzy V., et al.
Publicado: (2018)

Severe hypoglycaemia in adults with insulin‐treated diabetes: impact on healthcare resources
por: Heller, S. R., et al.
Publicado: (2015)

Insulin Autoimmune Syndrome: a rare case of hypoglycaemia resolving with immunosuppression.
por: Hunter, A, et al.
Publicado: (2018)

Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus
por: Frier, Brian M., et al.
Publicado: (2019)

Short Report: Treatment Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal–Bolus Type 1): 2-year results of a randomized clinical trial
por: Bode, B W, et al.
Publicado: (2013)

Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase
por: Morrow, Linda, et al.
Publicado: (2013)

The consequences of hypoglycaemia
por: Amiel, Stephanie A.
Publicado: (2021)

Glucose/insulin-glargine/insulin-lispro: Hepatic glycogenosis, hypoglycaemia and acute hepatitis: case report
Publicado: (2021)

Inhaled insulin for controlling blood glucose in patients with diabetes
por: Silverman, Bernard L, et al.
Publicado: (2007)

HYPO-CHEAT’s aggregated weekly visualisations of risk reduce real world hypoglycaemia
por: Worth, Chris, et al.
Publicado: (2022)

Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes
por: Rodbard, H W, et al.
Publicado: (2014)

Hypoglycaemia in adults with insulin‐treated diabetes in the UK: self‐reported frequency and effects
por: Frier, B. M., et al.
Publicado: (2015)

Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study
por: Akturk, Halis Kaan, et al.
Publicado: (2018)

Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2
por: Heller, Simon R., et al.
Publicado: (2019)

Does hypoglycaemia affect the improvement in QoL after the transition to insulin in people with type 2 diabetes?
por: Wieringa, T. H., et al.
Publicado: (2017)

3-point major cardiovascular event outcome for patients with T2D treated with dipeptidyl peptidase-4 inhibitor or glucagon-like peptide-1 receptor agonist in addition to metformin monotherapy
por: El Sanadi, Caroline E., et al.
Publicado: (2020)

Hypoglycaemia in adrenal insufficiency
por: Lee, Shien Chen, et al.
Publicado: (2023)

Practical application of short-term intensive insulin therapy based on the concept of “treat to target” to reduce hypoglycaemia in routine clinical site
por: Nakashima, Koji, et al.
Publicado: (2020)

Prolonged insulin-induced hypoglycaemia reduces ß-cell activity rather than number in pancreatic islets in non-diabetic rats
por: Jensen, Vivi F. H., et al.
Publicado: (2022)

Basal Insulin Reduces Glucose Variability and Hypoglycaemia Compared to Premixed Insulin in Type 2 Diabetes Patients: A Study Based on Continuous Glucose Monitoring Systems
por: Wang, Huiying, et al.
Publicado: (2022)

Reducing the burden of hypoglycaemia in people with diabetes through increased understanding: design of the Hypoglycaemia REdefining SOLutions for better liVEs (Hypo‐RESOLVE) project
por: de Galan, B. E., et al.
Publicado: (2020)

Hypoglycaemia due to insulin therapy for the management of hyperkalaemia in hospitalised adults: A scoping review
por: Chothia, Mogamat-Yazied, et al.
Publicado: (2022)

A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design
por: Kristensen, Peter Lommer, et al.
Publicado: (2012)

Limited impact of impaired awareness of hypoglycaemia and severe hypoglycaemia on the inflammatory profile of people with type 1 diabetes
por: Ali, Namam, et al.
Publicado: (2020)

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes
por: Home, P D, et al.
Publicado: (2015)

Diabetes: how to manage patients experiencing hypoglycaemia
por: Lowe, Rachel N, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q78apq5ip42bao12a71in83h3t